ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "radiography and rheumatoid arthritis (RA)"

  • Abstract Number: 559 • 2018 ACR/ARHP Annual Meeting

    Radiographic Progression Based on Baseline Demographics and Disease Characteristics from Three TNF-Alpha Inhibitor Biosimilar Studies in Patients with Rheumatoid Arthritis

    Josef S. Smolen1, Young Mo Kang2, Wan-Hee Yoo3, Paul Emery4, Michael E Weinblatt5, Edward C. Keystone6, Mark C. Genovese7, Gihyun Myung8, Evelyn Hong8, Inyoung Baek8 and Jeehoon Ghil8, 1Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, 2Kyungpook National University School of Medicine, Daegu, Korea, Republic of (South), 3Chonbuk National University School of Medicine, Jeonju, Korea, Republic of (South), 4University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, 5Brigham and Women's Hospital, Boston, MA, 6Mount Sinai Hospital, Toronto, ON, Canada, 7Stanford University Medical Center, Palo Alto, CA, 8Samsung Bioepis Co., Ltd., Incheon, Korea, Republic of (South)

    Background/Purpose: SB4, SB2, and SB5 are biosimilars of reference etanercept, infliximab, and adalimumab, respectively. Radiographic data were assessed using the modified Total Sharp Score (mTSS)…
  • Abstract Number: 890 • 2018 ACR/ARHP Annual Meeting

    A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib to Placebo and to Adalimumab, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Methotrexate

    Roy Fleischmann1, Aileen L. Pangan2, Eduardo Mysler3, Louis Bessette4, Charles Peterfy5, Patrick Durez6, Andrew Ostor7, Yihan Li2, Yijie Zhou2, Ahmed A. Othman2, In-Ho Song8 and Mark C. Genovese9, 1University of Texas Southwestern Medical Center at Dallas, Metroplex Clinical Research Center, Dallas, TX, 2AbbVie, Inc., North Chicago, IL, 3Organización Medica de Investigación, Buenos Aires, Argentina, 4Laval University, Québec, QC, Canada, 5Spire Sciences LLC, Boca Raton, FL, 6Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, 7Cabrini Medical Center, Malvern, Australia, 8AbbVie, Inc., north chicago, IL, 9Stanford University Medical Center, Palo Alto, CA

    Background/Purpose: To assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib (UPA), a JAK1- selective inhibitor, vs placebo (PBO) and active comparator, originator…
  • Abstract Number: 1450 • 2018 ACR/ARHP Annual Meeting

    Clinical Radiology Reports Are Unreliable for Assessment of Radiographic Structural Progression in US Veterans with Rheumatoid Arthritis Initiating Tumor Necrosis Factor Inhibitor Therapy

    Kevin R. Lammert1, Alan R. Erickson2, Brian C. Sauer1 and Grant W. Cannon1, 1Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 2Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Rheumatologists rely on hand radiograph findings including bone erosions (BE) and joint space narrowing (JSN) to make treatment decisions for patients with rheumatoid arthritis…
  • Abstract Number: 1454 • 2018 ACR/ARHP Annual Meeting

    Levels of 14-3-3eta Are an Independent Predictor of Long-Term Radiographic Erosive Progression and of Short-Term Rapid Radiographic Erosive Progression in Patients with Inflammatory Polyarthritis

    Gilles Boire1, Nathalie Carrier2, Artur J deBrum Fernandes3, Patrick Liang1, Ariel Masetto4, Sophie Roux4, Norma K Biln5, Yuan Gui5, Jane Savill5, Sara Michienzi5 and Walter P. Maksymowych6, 1Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, 2Centre intégré universitaire de santé et de services sociaux de l'Estrie -Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, 3Medicine, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, 4Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, 5Augurex Life Sciences Corp, Vancouver, BC, Canada, 6Department of Medicine, CaRE Arthritis and University of Alberta, Edmonton, Canada, Edmonton, AB, Canada

    Background/Purpose: Our objective is to examine the additional contribution of 14-3-3η levels to known predictors of radiographic progression in inflammatory polyarthritis, both over several years…
  • Abstract Number: 1455 • 2018 ACR/ARHP Annual Meeting

    Development of a Predictive Model of Radiological Damage in Patients with Rheumatoid Arthritis Based on Artificial Intelligence

    Jose M Lezcano1, José Ivorra-Cortes2, Alfredo Madrid3, Raquel Lopez-Mejías4, Javier Martin5, Benjamín Fernández-Gutiérrez6, Miguel Angel González-Gay7, Alejandro Balsa8, Isidoro Gonzalez-Alvaro9, Fernando Salazar10, Lydia A Alcazar11 and Luis Rodriguez-Rodriguez11, 1Helix BioS CEO, Madrid, Spain, 2Rheumatology, University Hospital la Fe, Valencia, Spain, 3Rheumatology Department, and Instituto de Investigación Sanitaria (IdISSC), Hospital Clínico San Carlos, Madrid, Spain, 4Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, 5Instituto de Parasitología y Biomedicina López Neyra, Granada, Spain, 6Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, 7School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain, 8Rheumatology Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, 9Rheumatology Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, 10International Centre for Numerical Methods in Engineering (CIMNE), Madrid, Spain, 11Rheumatology Department and Heath Research Institute (IdISSC), Hospital Clinico San Carlos, Madrid, Spain

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with increased mortality and disability. Although different factors have been associated with prognosis, it is…
  • Abstract Number: 429 • 2017 ACR/ARHP Annual Meeting

    Repair of Joint Damage Is Rare in Newly Diagnosed Rheumatoid Arthritis Patients and Appears Not to Relate to Previous Suppression of Inflammation

    Joy A. van der Pol1, Gulsah Akdemir1, Marianne van den Broek1, Linda Dirven1, Pit J.S.M. Kerstens2, Willem F. Lems3, Iris M. Markusse1, Cornelia F Allaart1 and Tom W.J. Huizinga1, 1Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, 2Department of Rheumatology, Reade, Amsterdam, Netherlands, 3Department of Rheumatology, VU Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands

    Background/Purpose: Joint damage in RA is thought to be irreparable. We hypothesized that in patients in whom inflammation is persistently well suppressed, repair may be…
  • Abstract Number: 1352 • 2017 ACR/ARHP Annual Meeting

    The Relevance of Elevated CRP As an Inclusion Criterion in Clinical Trials in Patients with Rheumatoid Arthritis

    Craig Scoville1, Jessica L. Suboticki2, Sheng Zhong3 and Edward C. Keystone4, 1Idaho Falls Arthritis Clinic, Idaho Falls, ID, 2AbbVie Inc., Mettawa, IL, 3AbbVie Inc., North Chicago, IL, 4Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Elevated C-reactive protein (CRP) is often used as an entry criterion in clinical trials (CT) with rheumatoid arthritis (RA) patients (pts), resulting in the…
  • Abstract Number: 1435 • 2017 ACR/ARHP Annual Meeting

    Consistent Inhibition of Joint Destruction By Denosumab in Important Subgroups of Japanese Patients with Rheumatoid Arthritis: Pooled Analysis of Phase 2 and 3 Studies

    Yoshiya Tanaka1, Tsutomu Takeuchi2, Satoshi Soen3, Naoki Ishiguro4, Hisashi Yamanaka5, Toshiyuki Yoneda6, Sakae Tanaka7, Takaya Nitta8, Naoki Okubo9, Harry K. Genant10 and Désirée van der Heijde11, 1University of Occupational and Environmental Health, Kitakyushu, Japan, 2Keio University School of Medicine, Tokyo, Japan, 3Kindai University Nara Hospital, Ikoma, Japan, 4Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, 5Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 6Indiana University School of Medicine, Indianapolis, IN, 7Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Bunkyo-ku, Japan, 8Daiichi Sankyo Co., Ltd., Tokyo, Japan, 9DaiichiSankyo CO., LTD., Tokyo, Japan, 10University of California, San Francisco, CA, 11Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Denosumab is a fully human monoclonal antibody (IgG2 subclass) that inhibits bone resorption by blocking RANKL. Phase 2 (DRIVE) and phase 3 (DESIRABLE) studies…
  • Abstract Number: 2909 • 2017 ACR/ARHP Annual Meeting

    Only Very High Radiographic Progression Affects HAQ-DI, Results from the Swiss Scqm Cohort

    Ruediger Mueller1, Reto Thalmann2, Hendrik Schulze-Koops3, Nicole Graf4 and Johannes von Kempis2, 1Rheumatology, MD, St. Gallen, Switzerland, 2Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, 3Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, 4Graf Biostatistics, Winterthur, Switzerland

    Background/Purpose: The aim of treatment of rheumatoid arthritis is to control disease activity and to inhibit joint damage. Progression of damage is analysed by conventional…
  • Abstract Number: 506 • 2016 ACR/ARHP Annual Meeting

    The Relationship Between Elevations in CRP with Physical Function and Radiographic Progression over the Long-Term in Patients with Rheumatoid Arthritis

    Arthur Kavanaugh1, Boulos Haraoui2, Prashanth Sunkureddi3, Benjamin Wolfe4, Li Wang4, Jessica Suboticki4 and Edward Keystone5, 1University of California San Diego, La Jolla, CA, 2University of Montreal, Montreal, QC, Canada, 3University of Texas Medical Branch, Galveston, TX, 4AbbVie Inc., North Chicago, IL, 5Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada

    Background/Purpose: For patients (pts) with rheumatoid arthritis (RA), quantification of radiographic progression, through measures such as modified total Sharp score (mTSS), is not routinely captured…
  • Abstract Number: 578 • 2016 ACR/ARHP Annual Meeting

    Do Specific Anti-Citrullinated Antibodies Predict Different Phenotype of Rheumatoid Arthritis?

    Mikael Brink1, Monika Hansson2, Linda Mathsson-Alm3,4, Johan Rönnelid5, Karl Skriner6, Guy Serre7, Lars Klareskog2 and Solbritt Rantapää-Dahlqvist1, 1Rheumatology, Umeå University, Umeå, Sweden, 2Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 3ThermoFisher Scientific, Uppsala, Sweden, Uppsala, Sweden, 4Thermo Fisher Scientific, Uppsala, Sweden, 5Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, 6Humboldt University of Berlin, Berlin, Germany, 7Unité Différenciation Épidermique et Autoimmunité Rhumatoïde, Unité Mixte de Recherche, INSERM, Toulouse, France

    Background/Purpose:  Antibodies against cyclic citrullinated peptides (anti-CCP) have been suggested to identify a more severe phenotype of rheumatoid arthritis. In this study we have analysed…
  • Abstract Number: 588 • 2016 ACR/ARHP Annual Meeting

    Radiographic Progression Is Less Significant in Anti-Carbamylated Antibody-Positive Patients with Rheumatoid Arthritis (RA) Who Were Clinically Active and Under the Treatment with Biological Dmards

    Kazuko Shiozawa1, Ken Tsumiyama2 and Shunichi Shiozawa2, 1The Rheumatic Diseases Center, Kohnan Kakogawa Hospital, Kakogawa, Japan, 2Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan

    Background/Purpose: A newly discovered anti-carbamylated protein antibody (anti-CarP) is found prior to disease-onset, associates with the conversion towards arthralgia and with a more severe disease…
  • Abstract Number: 926 • 2016 ACR/ARHP Annual Meeting

    Increased Concentration of Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) Predate Onset of Rheumatoid Arthritis

    Linda Johansson1, Lisbeth Ärlestig1, Heidi Kokkonen2 and Solbritt Rantapaa-Dahlqvist3, 1Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, 2Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, 3Umeå University, Department of Public Health and Clinical Medicine/ Rheumatology, Umeå, Sweden

    Background/Purpose:  Receptor activator of nuclear factor κB ligand (RANKL) an important regulator of bone metabolism has a key role in local bone destruction and osteoporosis…
  • Abstract Number: 2081 • 2016 ACR/ARHP Annual Meeting

    Dermal Temperature Is an Excelent Prognostic Indicator to Guide RA Therapy

    JoAnn Ball1 and Maria Greenwald2, 1rheumatology, Desert Medical Advances, Palm Deseret, CA, 2Rheumatology, Desert Medical Advances, Palm Desert, CA

    Background/Purpose: Nurses and rheumatology extenders can rapidly identify rheumatoid arthritis (RA) patients who flare, with high predictive value for which individual is at high risk…
  • Abstract Number: 2591 • 2016 ACR/ARHP Annual Meeting

    Association Between Flare and Radiographic Progression in Patients with Rheumatoid Arthritis

    Josef Smolen1, Heather Jones2, Ehab Mahgoub2, Ronald Pedersen3 and Lisa Marshall2, 1Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, 3Department of Biostatistics, Pfizer, Collegeville, PA

    Background/Purpose: Biologic therapy has improved RA management and enabled some patients to achieve remission. Many clinicians decrease the biologic dose for patients in low disease…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology